Kawazoe Hitoshi, Sumikawa Satomi, Nakauchi Kana, Yakushijin Yoshihiro, Yamamoto Yuji, Watanabe Yuji, Tanaka Akihiro, Araki Hiroaki
Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime, Japan.
Division of Nursing, Ehime University Hospital, Shitsukawa, Toon, Ehime, Japan.
Int J Clin Pharm. 2017 Dec;39(6):1291-1297. doi: 10.1007/s11096-017-0536-1. Epub 2017 Oct 13.
Background Venous pain induced by peripheral intravenous administration of oxaliplatin remains clinically unresolved. Objective The aim of this study was to determine the efficacy of comprehensive intervention care for venous pain in colorectal cancer patients receiving oxaliplatin. Setting A Japanese tertiary hospital. Method We treated all outpatients after April 2012 with comprehensive intervention care including pre-warming of the oxaliplatin solution, use of a hot compress, and pH adjustment by combination with dexamethasone. We retrospectively reviewed the electronic medical records from colorectal cancer patients who had received oxaliplatin via a peripheral vein between December 2009 and June 2014. Main outcome measures The primary endpoint of this study was the incidence of venous pain at the administration site during oxaliplatin infusion, according to injection site reaction grade ≥ 2. Results We evaluated 271 treatment courses in 59 patients. Venous pain occurred in 42 courses (15.5%) among 26 patients. Multivariate logistic regression analysis revealed that female gender and body mass index ≥ 25 kg/m were significantly associated with an increased risk of venous pain during all courses (adjusted odds ratio [OR]: 3.18, 95% confidence interval [CI] 1.35-7.92; P < 0.01; and adjusted OR: 3.37, 95% CI 1.26-9.40; P = 0.02, respectively), whereas comprehensive intervention care were significantly associated with reduced risk of venous pain during all courses (adjusted OR: 0.10, 95% CI 0.02-0.44; P < 0.01). Conclusion Comprehensive intervention care is a clinical treatment option for oxaliplatin-induced peripheral venous pain in patients with colorectal cancer, especially females with obesity.
背景 外周静脉输注奥沙利铂引起的静脉疼痛在临床上仍未得到解决。
目的 本研究旨在确定综合干预护理对接受奥沙利铂治疗的结直肠癌患者静脉疼痛的疗效。
地点 日本一家三级医院。
方法 自2012年4月起,我们对所有门诊患者采用综合干预护理,包括奥沙利铂溶液预加温、热敷以及联合地塞米松进行pH值调节。我们回顾性分析了2009年12月至2014年6月期间经外周静脉接受奥沙利铂治疗的结直肠癌患者的电子病历。
主要观察指标 本研究的主要终点是根据注射部位反应分级≥2级,在奥沙利铂输注期间给药部位静脉疼痛的发生率。
结果 我们评估了59例患者的271个疗程。26例患者的42个疗程(15.5%)出现静脉疼痛。多因素逻辑回归分析显示,女性和体重指数≥25kg/m在所有疗程中均与静脉疼痛风险增加显著相关(校正比值比[OR]:3.18,95%置信区间[CI]1.35 - 7.92;P<0.01;校正OR:3.37,95%CI 1.26 - 9.40;P = 0.02),而综合干预护理在所有疗程中均与静脉疼痛风险降低显著相关(校正OR:0.10,95%CI 0.02 - 0.44;P<0.01)。
结论 综合干预护理是结直肠癌患者奥沙利铂所致外周静脉疼痛的一种临床治疗选择,尤其是肥胖女性患者。